Tonix Pharmaceuticals Holding (TNXP) Receivables - Other (2022 - 2026)

Tonix Pharmaceuticals Holding has reported Receivables - Other for 5 years, with the latest figure at $3.2 million in Q2 2026.

• On a quarterly basis, Receivables - Other rose 60.35% year-over-year to $3.2 million in Q2 2026; TTM through Jun 2026 was $3.2 million, a 60.35% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, up 265.69% from the prior year.
• Receivables - Other was $3.2 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from $3.4 million in the prior quarter.
• The five-year high for Receivables - Other was $8.0 million in Q4 2022, with the low at $300000.0 in Q1 2024.
• Average Receivables - Other over 5 years is $2.4 million, with a median of $1.8 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other tumbled 80.79% in 2024, then surged 575.0% in 2025.
• Over 5 years, Receivables - Other stood at $8.0 million in 2022, then plunged by 42.93% to $4.6 million in 2023, then tumbled by 79.24% to $953000.0 in 2024, then jumped by 265.69% to $3.5 million in 2025, then slipped by 6.83% to $3.2 million in 2026.
• The last three Receivables - Other figures came in at $3.2 million (Q2 2026), $3.4 million (Q1 2026), and $3.5 million (Q4 2025), per Business Quant data.